Affinity Asset Advisors, LLC Verona Pharma PLC Transaction History
Affinity Asset Advisors, LLC
- $596 Million
- Q2 2025
A detailed history of Affinity Asset Advisors, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 610,000 shares of VRNA stock, worth $64.2 Million. This represents 9.68% of its overall portfolio holdings.
Number of Shares
610,000
Previous 615,000
0.81%
Holding current value
$64.2 Million
Previous $39 Million
47.76%
% of portfolio
9.68%
Previous 4.36%
Shares
12 transactions
Others Institutions Holding VRNA
# of Institutions
325Shares Held
78.3MCall Options Held
883KPut Options Held
3M-
Janus Henderson Group PLC London, X06.13MShares$645 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$579 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$434 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$356 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$321 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.41B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...